Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H20N4O2 |
| Molecular Weight | 336.3877 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCCC(C1)C(=O)N2C3=CC=CC=C3NC(=O)C4=CC=CN=C24
InChI
InChIKey=LPLNSPKKMWHFAU-UHFFFAOYSA-N
InChI=1S/C19H20N4O2/c1-22-11-5-6-13(12-22)19(25)23-16-9-3-2-8-15(16)21-18(24)14-7-4-10-20-17(14)23/h2-4,7-10,13H,5-6,11-12H2,1H3,(H,21,24)
| Molecular Formula | C19H20N4O2 |
| Molecular Weight | 336.3877 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Rispenzepine (DF 594) is a muscarinic receptor antagonist. Rispenzepine has high affinity for intestinal muscarinic receptors, with preferential action at M1 and M3 receptor subtypes. This drug shows potent inhibitory effects on intestinal motility. In guinea pigs, rispenzepine significantly increases acetylcholine release in the trachea. A phase II study to test efficacy in asthma patients has been discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:45:59 GMT 2025
by
admin
on
Mon Mar 31 18:45:59 GMT 2025
|
| Record UNII |
W99LLM73R7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
96449-05-7
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
W99LLM73R7
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106612
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
SUB10334MIG
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
DTXSID60869271
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
100000080572
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
129505
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
6521
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY | |||
|
C74175
Created by
admin on Mon Mar 31 18:45:59 GMT 2025 , Edited by admin on Mon Mar 31 18:45:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |